The new law includes requirements that drugmakers reveal discounts for pharmacy benefit managers and prevents gag rules on pharmacists who want to suggest cheaper alternatives.
Backed by his state’s powerful Culinary Union, Nevada Governor Brian Sandoval last week signed the nation’s most far-reaching transparency law aimed at requiring insulin manufacturers to reveal how they set prices.
Supporters of the law say its purpose is to protect people with diabetes who depend on insulin from unexplained price increases, which they say have come with more frequency and are threatening the health and finances of people with both type 1 diabetes (T1D) and type 2 diabetes (T2D).
A statement from the Culinary Union, which represents 57,000 workers in Las Vegas and Reno, said that diabetes costs Nevada $2.4 billion in medical costs and that 1 out of every 3 people who lives in the state has diabetes or prediabetes. An estimated 12% of Nevadans have diabetes.
As he signed the bill, Sandoval, a Republican, said one of the people affected by insulin prices was his grandfather. “This was my mom’s dad, and he’s somebody I saw suffer because of that,” he said, in remarks reported by the Las Vegas Review-Journal. He had declined to sign an earlier version of the legislation because he wanted greater focus on what he called the “middlemen” who play a role in price increases: the pharmacy benefit managers (PBMs). The law Sandoval signed includes such a provision.
Insulin manufacturers issued letters in opposition to the earlier version of the legislation. Published reports noted the muted response from well-known advocacy groups, and that the Culinary Union was the main force behind the bill.
Provisions in the final version include:
Spokespersons for PBMs have suggested that the law’s requirements resemble rules that have been struck down at the federal level.
The cost of insulin has been the topic of hearings in Congress and sparked a class action lawsuit earlier this year.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen